Gan & Lee Pharmaceuticals released its semi-annual performance report, with a net profit attributable to the parent company of 604 million yuan, a year-on-year increase of 101.96%
I'm LongbridgeAI, I can summarize articles.Gan & Lee Pharmaceuticals released its semi-annual report for 2025, with revenue of 2.067 billion yuan, a year-on-year increase of 57.18%; net profit attributable to the parent company of 604 million yuan, a year-on-year increase of 101.96%. The net profit excluding non-recurring items was 488 million yuan, a year-on-year increase of 284.47%. Domestic sales revenue was 1.845 billion yuan, a year-on-year increase of 55.28%, while international revenue was 222 million yuan, a year-on-year increase of 75.08%. The company expanded its market share through insulin centralized procurement, achieving growth in both sales volume and price, providing support for revenue growth
According to the Zhitong Finance APP, Gan & Lee (603087.SH) disclosed its semi-annual report for 2025, reporting revenue of 2.067 billion yuan, a year-on-year increase of 57.18%, and a net profit attributable to shareholders of the listed company of 604 million yuan, a year-on-year increase of 101.96%; the net profit after deducting non-recurring gains and losses was 488 million yuan, a year-on-year increase of 284.47%; basic earnings per share were 1.02 yuan.
Domestic sales revenue was 1.845 billion yuan, an increase of 655 million yuan compared to the same period last year, representing a year-on-year growth of 55.28%. Among them, domestic formulation sales revenue was 1.802 billion yuan, a year-on-year increase of 57.09%. Through two rounds of insulin centralized procurement, the company successfully achieved its strategic goal of expanding market share. Especially in the follow-up centralized procurement in 2024, the procurement agreement volume in the first year of centralized procurement increased by 32.6% compared to the last centralized procurement, while product prices reasonably rebounded. During the reporting period, with the in-depth implementation of the new round of insulin centralized procurement policy, the company leveraged the market coverage advantages gained from centralized procurement, deeply cultivated various market levels, and fully released the synergistic effects of volume and price increases, providing strong support for revenue growth. The impact of sales volume growth on revenue growth was 385 million yuan, and the impact of price growth on revenue growth was 270 million yuan. In addition, the overall sales volume of the company's domestic formulations increased by 33.55% year-on-year, with all formulation products showing positive growth trends.
International revenue was 222 million yuan, an increase of 95 million yuan compared to the same period last year, representing a year-on-year growth of 75.08%. This was mainly due to the company's ongoing globalization strategy. During the reporting period, the company continued to deepen stable cooperative relationships with key market leading partners, relying on customer trust to promote a diverse product portfolio, explore new cooperation potential, and develop new growth points for collaboration